Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP1873)

• Drug Name: TAK-063 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 46848915
  CAS Number: CAS 1238697-26-1
  TTD Drug ID: DMP1873

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 10A (PDE10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[3]
PF-02545920	DMJPE61	Huntington disease	8A01.10	Phase 2	[4]
OMS824	DMA4OGL	Huntington disease	8A01.10	Phase 2	[5]
Lu AF11167	DMJOYNZ	Schizophrenia	6A20	Phase 2	[6]
FRM-6308	DMNCOE1	Schizophrenia	6A20	Phase 1b	[7]
PBF-999	DMBSQH9	Huntington disease	8A01.10	Phase 1	[8]
RG7203	DMYX4NP	Schizophrenia	6A20	Phase 1	[9]
AMG 579	DMRMC7U	Schizophrenia	6A20	Phase 1	[10]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[11]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	DM4CSBD	N. A.	N. A.	Patented	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 10A (PDE10)	TTJW4LU	PDE10_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02477020) A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia.
• [2] Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
• [3] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
• [6] PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
• [7] Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
• [8] Clinical pipeline report, company report or official report of Palobiofarma.
• [9] Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013
• [10] Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.
• [11] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.